Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Credit NIAID-RML
Highlighted Sections
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Revised Statement on Evusheld
The Panel now recommends against the use of tixagevimab plus cilgavimab for pre-exposure prophylaxis (PrEP) of COVID-19.
Overview of COVID-19
This section discusses the recent data on disparities in COVID-19-related health outcomes, access to care, and receipt of treatment among racial and ethnic minority groups.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Interleukin-1 Inhibitors
The Panel has added information about the Food and Drug Administration’s Emergency Use Authorization for anakinra.
Table: Systemic Corticosteroids Clinical Data
This table presents clinical data on the use of systemic corticosteroids for the treatment of COVID-19.
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Revised Statement on Evusheld
The Panel now recommends against the use of tixagevimab plus cilgavimab for pre-exposure prophylaxis (PrEP) of COVID-19.
Overview of COVID-19
This section discusses the recent data on disparities in COVID-19-related health outcomes, access to care, and receipt of treatment among racial and ethnic minority groups.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Interleukin-1 Inhibitors
The Panel has added information about the Food and Drug Administration’s Emergency Use Authorization for anakinra.
Table: Systemic Corticosteroids Clinical Data
This table presents clinical data on the use of systemic corticosteroids for the treatment of COVID-19.
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Revised Statement on Evusheld
The Panel now recommends against the use of tixagevimab plus cilgavimab for pre-exposure prophylaxis (PrEP) of COVID-19.
Overview of COVID-19
This section discusses the recent data on disparities in COVID-19-related health outcomes, access to care, and receipt of treatment among racial and ethnic minority groups.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Interleukin-1 Inhibitors
The Panel has added information about the Food and Drug Administration’s Emergency Use Authorization for anakinra.
Table: Systemic Corticosteroids Clinical Data
This table presents clinical data on the use of systemic corticosteroids for the treatment of COVID-19.